Company Encyclopedia
View More
name
Xingqi Pharmaceutical
300573.SZ
Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People’s Republic of China. The company provides myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory/anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs, intraocular rinsing fluids, pupil dilatant and ciliary muscle paralyzers, anti-fatigue medicines, and dry eye medicines. It also engages in the technology development, technical consultation, and eye hospital businesses, as well as production and wholesale of pharmaceuticals.
3.165 T
300573.SZMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
A
PharmaceuticalsIndustry
Industry Ranking2/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE37.08%A
    • Profit Margin26.84%A
    • Gross Margin83.38%A
  • Growth ScoreA
    • Revenue YoY33.62%A
    • Net Profit YoY85.44%A
    • Total Assets YoY10.69%B
    • Net Assets YoY14.10%A
  • Cash ScoreB
    • Cash Flow Margin372.61%C
    • OCF YoY33.62%A
  • Operating ScoreA
    • Turnover1.05A
  • Debt ScoreB
    • Gearing Ratio23.24%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue

    Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue

    marketscreener·
    SZ
    300573
    +0.22%
    marketscreener·
    SZ
    300573
    +0.22%

    Xingqi Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 599 million yuan, an increase of 105.98%

    Xingqi Pharmaceutical released its Q3 2025 report, with operating revenue for the first three quarters reaching 1.904 billion yuan, a year-on-year increase of 32.27%; net profit attributable to shareholders was 599 million yuan, a year-on-year increase of 105.98%; net profit excluding non-recurring gains and losses was 596 million yuan, a year-on-year increase of 105.76%; basic earnings per share were 2.44 yuan

    Zhitong·
    SZ
    300573
    +0.22%
    Zhitong·
    SZ
    300573
    +0.22%

    Xingqi Pharmaceutical: SQ-129 vitreous body sustained-release injection has obtained clinical trial approval

    Xingqi Pharmaceutical announced that its developed SQ-129 vitreous sustained-release injection has received clinical trial approval from the National Medical Products Administration. This drug is a Class 2 modified new drug aimed at treating diabetic macular edema in adult patients and macular edema caused by retinal branch vein occlusion or central vein occlusion. Studies have shown that this drug has good safety and clinical development value, and currently, there are no similar products approved for market

    Zhitong·
    SZ
    300573
    +0.22%
    Zhitong·
    SZ
    300573
    +0.22%

    Xingqi Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 335 million yuan, an increase of 97.75%

    According to the Zhitong Finance APP, Xingqi Pharmaceutical released its semi-annual report for 2025, with operating revenue of 1.163 billion yuan, a year-on-year increase of 30.38%. The net profit attributable to shareholders of the listed company was 335 million yuan, a year-on-year increase of 97.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 331 million yuan, a year-on-year increase of 96.30%. The basic earnings per share were 1.36 yuan

    Zhitong·
    SZ
    300573
    +0.22%
    Zhitong·
    SZ
    300573
    +0.22%

    Xingqi Pharmaceutical: Net profit in the first half of 2025 increased by 97.75% year-on-year, plans to distribute 7 yuan for every 10 shares

    Xingqi Pharmaceutical announced that in the first half of 2025, operating revenue reached 1.163 billion yuan, a year-on-year increase of 30.38%. Net profit was 335 million yuan, a year-on-year increase of 97.75%. It plans to distribute a cash dividend of 7 yuan for every 10 shares to all shareholders

    Zhitong·
    SZ
    300573
    +0.22%
    Zhitong·
    SZ
    300573
    +0.22%
    © 2025 Longbridge｜Disclaimer